guadecitabine (SGI-110) / Otsuka  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
guadecitabine (SGI-110) / Otsuka
ACTRN12618000028202: A phase 2, open label trial of guadecitabine (SGI-110) in patients with T-cell lymphoma

Completed
2
20
 
Monash Health, ASTEX Pharmaceuticals Inc.
T-cell lymphoma
 
 
NCT02901899: Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed
2
45
US
Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Northwestern University, Merck Sharp & Dohme LLC, Astex Pharmaceuticals, Inc., National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
04/20
03/23
2019-002986-36: A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1 Studio di fase II randomizzato con la combinazione nivolumab, ipilimumab e guadecitabina o la combinazione nivolumab e ipilimumab in pazienti affetti da melanoma e carcinoma polmonare non a piccole cellule metastatico resistente ad anti-PD-1/PD-L1

Ongoing
2
184
Europe
YERVOY, Guadecitabine, OPDIVO, [NA], [SGI-110], [na], Concentrate for solution for infusion, Lyophilisate for solution for injection, Solution for infusion
FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI, Bristol-Myers Squibb S.r.l, Astex Pharmaceutical, Inc
MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy pazienti con melanoma metastatico (MM) e tumore del polmone non a piccole cellule (NSCLC) in stadio IV, che hanno ricevuto e sono progrediti a precedenti trattamenti con farmaci immunoterapici anti-PD-1/(-PD-L1), MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy pazienti con melanoma metastatico (MM) e tumore del polmone non a piccole cellule (NSCLC) in stadio IV, che hanno ricevuto e sono progrediti a precedenti trattamenti immunoterapici anti-PD-1/(-PD-L1), Diseases [C] - Cancer [C04]
 
 
NCT03179943: Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Active, not recruiting
2
21
US
Atezolizumab, Guadecitabine
Fox Chase Cancer Center, Stand Up To Cancer, Van Andel Research Institute
Urothelial Carcinoma
07/20
07/22
NCT03913455: Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Completed
2
24
US
Guadecitabine, SGI-110, Carboplatin, Platinol
Shadia Jalal, MD, Astex Pharmaceuticals, Inc., Indiana University School of Medicine
Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
04/21
02/22
NIBIT-ML1, NCT04250246: A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

Not yet recruiting
2
184
Europe
Ipilimumab plus nivolumab plus guadecitabine, ipilimumab (Yervoy), nivolumab (Opdivo), guadecitabine (SGI-110), Ipilimumab plus nivolumab
Italian Network for Tumor Biotherapy Foundation, Astex Pharmaceuticals, Inc., Bristol-Myers Squibb
Melanoma, Non Small Cell Lung Cancer
03/23
03/25
NCI-2014-02377, NCT02131597: Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

Active, not recruiting
2
71
US
Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
High Risk Myelodysplastic Syndrome
11/24
11/24
ETCTN, NCT04340843: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Active, not recruiting
2
32
US
Belinostat, Beleodaq, PXD 101, PXD101, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
01/25
01/25
NCI-2016-00343, NCT02684162: Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Active, not recruiting
2
55
US
Donor Lymphocytes, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
12/24
12/24
2015-004062-29: SPIRE - A phase Ib/randomised IIa open label clinical trial combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer

Ongoing
1/2
56
Europe
Guadecitabine (SGI-110), Cisplatin, Gemcitabine, SGI-110, Powder for injection, Concentrate for solution for injection/infusion, Powder for infusion
University Hospital Southampton NHS Trust, Cancer Research UK, Astex Pharmaceuticals
Solid Malignancies including Bladder Cancer, Bladder Cancer, Diseases [C] - Cancer [C04]
 
 
BTCRC GU16-043, NCT03308396: Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Active, not recruiting
1/2
57
US
Guadecitabine, SGI-110, Durvalumab, MEDI4736
Ajjai Alva, MD, AstraZeneca, Big Ten Cancer Research Consortium
Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma
12/22
12/23
NCI-2016-01233, NCT02935361: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Active, not recruiting
1/2
33
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110
University of Southern California, National Cancer Institute (NCI), Van Andel Research Institute
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
11/24
11/25
NCT03206047: Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
1/2
75
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, CDX-1401, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110, Laboratory Biomarker Analysis, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid
National Cancer Institute (NCI)
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/25
03/25

Download Options